Talion: Full Drug Profile

Talion - General Information

Talion is a non-sedating, selective antagonist of the histamine 1 (H1) receptor. Talion was approved in Japan for use in the treatment of allergic rhinitis and uriticaria/puritus in July 2000 and January 2002, respectively, and is marketed by Tanabe Seiyaku Co., Ltd. under the brand name Talion®. It is currently undergoing trials in the U.S.

Pharmacology of Talion

Talion is a non-sedating, selective antagonist of the histamine 1 (H1) receptor. It has a stabilizing effect on mast cells, and it suppresses the migration of eosinophils into inflamed tissues. Talion is under investigation in an eye drop formulation by Ista for the treatment of allergic conjunctivitis. An oral formulation of this drug is approved in Japan for the treatment of allergic conjunctivitis and uriticaria/puritus. Ista Pharm. filed an IND with the FDA for bepotastine in December of 2006.

Additional information about Talion

Talion Indication

For the treatment of allergic conjunctivitis and uriticaria/puritus.

Mechanism Of Action

Talion has three primary mechanisms of action. It is a non-sedating, selective antagonist of the histamine 1 (H1) receptor, it has a stabilizing effect on mast cells, and it suppresses the migration of eosinophils into inflamed tissues.

Generic Name

Bepotastine

Synonyms

Bepotastine besilate; Betotastine besilate; TAU-284DS

Drug Category

Antihistamines; Histamine H1 Antagonists, Non-Sedating; Anti-Allergic Agents

Drug Type

Small Molecule; Approved; Investigational

Other Brand Names containing Bepotastine

Talion;

Absorption

High oral absorption

Dosage Forms of Talion

Tablet Oral

Chemical IUPAC Name

4-[4-[(4-chlorophenyl)-pyridin-2-ylmethoxy]piperidin-1-yl]butanoic acid

Chemical Formula

C21H25ClN2O3

Organisms Affected

Humans and other mammals